Danielle Holtschlag

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.

Arteriocyte Medical Systems, Inc. develops and markets novel medical products. The firms products include Magellan, Magellan PRP, mar0max, mar0match and mar0fuse. It divisions include compass biomedical and discover truPRP. The company was founded in 2007 and is headquartered in Hopkinton, MA.

Arteriocyte, Inc. provides clinical stage research and develops biotechnology. It develops novel stem cell products and medical devices for unmet clinical needs. The company was founded by Vincent J. Pompili and Mary J. Laughlin in 2004 and is headquartered in Cleveland, Ohio.